Keiffer Gina, French Zachary, Wilde Lindsay, Filicko-O'Hara Joanne, Gergis Usama, Binder Adam F
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States.
Front Oncol. 2020 Sep 18;10:562625. doi: 10.3389/fonc.2020.562625. eCollection 2020.
While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.
虽然少数严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者会发生细胞因子风暴，但对于发生细胞因子风暴的患者，迫切需要新的治疗方法。托珠单抗是一种白细胞介素-6受体抗体，已被用于治疗多种严重炎症性疾病中的细胞因子风暴，包括2019冠状病毒病（COVID-19）患者。在此，我们报告首例在有基础免疫缺陷的患者中使用该疗法的病例。我们的再生障碍性贫血患者因COVID-19发生细胞因子风暴，表现为发热、严重缺氧、肺部浸润和炎症标志物升高。使用托珠单抗治疗后，细胞因子风暴得到缓解，患者最终安全出院。
